(provided by the applicant): The UCLA APT CTU is a multidisciplinary, research group composed of a core administrative unit and four clinical research sites (CRS) in metropolitan Los Angeles and one CRS in Southern Brazil (Figure 1.1). We have over 20 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies in diverse populations across all age groups. Under the leadership of Judith Currier M.D., M.Sc. and an experienced multidisciplinary investigator team including Eric Daar, M.D., Margaret Keller, M.D., Karin Nielsen, M.D., Steve Shoptaw, Ph.D., Yvonne Bryson M.D., Ronald Mitsuyasu, M.D., Raphael Landovitz, M.D., Breno Santos, M.D., and Stephen Brown M.D., we will participate in the design and conduct of studies addressing the priority areas;Therapeutics for HIV/AIDS and HIV-Associated Infections in both Adults and Maternal/Pediatric Populations, Integrated Strategies to Prevent HIV Infection, and Vaccines to Prevent HIV Infection. The CTU has an administrative core and CRS at UCLA and additional CRSs at Harbor-UCLA Medical Center, UCLA Vine Street Clinic, AIDS Research Alliance (ARA) and in Porto Alegre, Brazil. The CTU provides a gateway for the contributions of a cadre of outstanding established and emerging investigators at UCLA to contribute to clinical trials in HIV/AIDS. The goal of the UCLA APT CTU is to enroll diverse populations (encompassing adult, maternal and pediatrics) of HIV-infected and at-risk individuals from urban Los Angeles and Southern Brazil into therapeutic and prevention trials.
The specific aims of our unit are to:
AIM 1 :To make significant contributions to the development, conduct and leadership of studies in adult, maternal and pediatric HIV therapeutics.
AIM 2 : To evaluate and optimize integrated strategies to prevent HIV infection in diverse populations AIM 3: To conduct Phase l-lll trials to evaluate novel vaccine strategies to prevent HIV in all age groups AIM 4: To mentor new investigators in cross-disciplinary HIV/AIDS research as it relates to improving treatment, care management and prevention in diverse populations, including substance users.
AIM 5 : To simulate and support community involvement in HIV/AIDS research by maintaining active CABs and by facilitating greater participation of women and racial/ethnic minorities in the clinical trils conducted at the UCLA APT CTU.
Worldwide there are 33 million people estimated to be living with HIV infection. Progress in the development of effective antiretroviral therapy and both biomedical and behavioral interventions for the prevention of HIV/AIDS has been phenomenal in the past thirty years, yet many important challenges remain. The clinical trials unit proposed will conduct high impact studies to evaluate new approaches to treating HIV infection and related complications and to preventing new cases of HIV through biomedical and vaccine research.
|Shivakoti, Rupak; Christian, Parul; Yang, Wei-Teng et al. (2016) Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr 35:183-9|
|Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-NaÃ¯ve Men and Women in the United States. AIDS Behav 20:2983-2995|
|Jacobson, Jeffrey M; Zheng, Lu; Wilson, Cara C et al. (2016) The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 71:163-71|
|Shivakoti, Rupak; Yang, Wei-Teng; Berendes, Sima et al. (2016) Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings. J Infect Dis 213:1074-8|
|Mave, Vidya; Erlandson, Kristine M; Gupte, Nikhil et al. (2016) Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis 214:65-72|
|Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+â€Š: â€ŠCD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7|
|Bigna, Jean Joel R; Plottel, Claudia S; Koulla-Shiro, Sinata (2016) Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infect Dis Poverty 5:85|
|Fogel, Jessica M; Hudelson, Sarah E; Ou, San-San et al. (2016) Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 72:304-9|
|Castillo-Mancilla, Jose R; Aquilante, Christina L; Wempe, Michael F et al. (2016) Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother 71:1609-18|
|Bedimo, Roger; Kang, Minhee; Tebas, Pablo et al. (2016) Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Res Hum Retroviruses 32:325-8|
Showing the most recent 10 out of 131 publications